Improvement in the immunological methods for the detection of human breast carcinomas.
A review is presented of the present situation regarding the use of various tumour-derived and tumour-associated changes in patients with breast carcinomas. The diagnosing and monitoring of breast carcinoma by the use of its presently recognized products is far from ideal. Some of the products, however, are of some value in assessing prognosis. A continued search for other products specific and functionally essential to breast cells appears to be worthwhile and timely.